| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating novel, small molecule drugs for viral infections and immunological diseases, today announced that data for zelicapavir, its oral, once-daily, N-protein inhibitor, and EDP-323, it's oral, once-daily L-protein inhibitor, both in development for the treatment of respiratory syncytial virus (RSV), will be presented at IDWeek™ 2025 being held October 19 - 22, 2025 virtually and at the Georgia World Congress Center in Atlanta, Georgia.
Details of the presentations are as follows:
Zelicapavir:
Rapid-Fire Presentation
Title: "Zelicapavir (EDP-938) Antiviral Treatment is Associated with Shortened Duration of RSV Symptoms in a Randomized, Double-Blind, Placebo-Controlled, Clinical Trial in Children 28 Days to 36 Months of Age"
Date: Monday, October 20, 2025
Time: 12:35 PM - 12:40 PM EDT
Presentation Number: 135
Session: Pediatric Respiratory Virus
Location: Poster Hall B4-B5 - Arena 2
Presenter: Dr. Christopher E. Harris
Poster
Title: "Zelicapavir (EDP-938) Antiviral Treatment is Associated with Shortened Duration of RSV Symptoms in a Randomized, Double-Blind, Placebo-Controlled, Clinical Trial in Children 28 Days to 36 Months of Age"
Date: Monday, October 20, 2025
Time: 12:15 PM - 1:30 PM EDT
Poster Number: 523
Session: Pediatric Viral Studies
Location: Poster Hall B4-B5
Presenter: Dr. Christopher E. Harris
EDP-323:
Oral Presentation
Presentation Title: "EDP-323, a First-in-Class, Oral, RSV-Specific, Non-Nucleoside L-Protein Inhibitor Antiviral Rapidly Reduces Total RSV Symptoms, Lower Respiratory Tract RSV Symptoms and Viral Load After Human Viral Challenge"
Date: Monday, October 20, 2025
Time: 4:15 PM - 4:27 PM EDT
Presentation Number: 235
Session: New Anti-Infective Agents
Location: B213-B214
Presenter: Dr. John P. DeVincenzo
Poster Presentation
Poster Title: "Post-Exposure Prophylaxis (PEP) of Respiratory Syncytial Virus (RSV) Infection After High-Inoculum RSV Human Challenge: Analysis of a Randomized Double-Blind, Placebo-Controlled Trial of EDP-323, an Oral, Non-Nucleoside Polymerase Inhibitor Antiviral"
Date: Wednesday, October 22, 2025
Time: 12:15 PM - 1:30 PM EDT
Poster Number: 2181
Session: Virology
Location: Poster Hall B4-B5
Presenter: Dr. John P. DeVincenzo
Posters will be available to view on the conference platform during the conference and on the Company's website here after presentations. Further information about IDWeek™ 2025 can be found here.
Posted In: ENTA
